A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)

This study investigates the initial safety profile of [18F]P17-059 in healthy volunteers including dosimetry determination, and compares regional brain uptake and kinetics of [18F]P17-059 in Parkinson's disease patients with regional brain uptake and kinetics of [18F]P17-059 in healthy volunteers.

Start Date15 Jul 2022

Sponsor / Collaborator

Five Eleven Pharma, Inc.

NCT05381103 / RecruitingPhase 2/3

PSMA-PET to Guide Prostatectomy: A Randomized Trial

In this study, 288 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluated in the context of affecting subsequent surgical plans and impacting actual patient outcomes.

Start Date01 Oct 2021

Sponsor / Collaborator

Five Eleven Pharma, Inc.

[+1]

NCT03444844 / Active, not recruitingPhase 1/2

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment

Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high risk primary prostate cancer patients.

Start Date10 May 2018

Sponsor / Collaborator

Five Eleven Pharma, Inc.

[+1]

100 Clinical Results associated with Five Eleven Pharma, Inc.

0 Patents (Medical) associated with Five Eleven Pharma, Inc.

Literatures (Medical) associated with Five Eleven Pharma, Inc.

01 Jul 2024·European Journal of Nuclear Medicine and Molecular Imaging

Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study

Article

Author: Wang, Rongxi ; Hong, Haiyan ; Sui, Huimin ; Zang, Jie ; Wang, Guochang ; Wang, Jiarou ; Zhu, Zhaohui ; Jiang, Yuanyuan ; Zhu, Lin ; Kung, Hank F ; Li, Linlin ; Alexoff, David ; Ploessl, Karl ; Jin, Wenbin ; Jia, Chenhao

PURPOSEProstate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [¹⁷⁷Lu]Lu-P17-087, and its albumin binder modified derivative, [¹⁷⁷Lu]Lu-P17-088, were evaluated in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary endpoint was dosimetry evaluation, the second endpoint was radiation toxicity assessment (CTCAE 5.0) and PSA response (PCWG3).METHODSPatients with PSMA-positive tumors were enrolled after [⁶⁸Ga]Ga-PSMA-11 PET/CT scan. Five mCRPC patients received [¹⁷⁷Lu]Lu-P17-087 and four other patients received [¹⁷⁷Lu]Lu-P17-088 (1.2 GBq/patient). Multiple whole body planar scintigraphy was performed at 1.5, 4, 24, 48, 72, 120 and 168 h after injection and one SPECT/CT imaging was performed at 24 h post-injection for each patient. Dosimetry evaluation was compared in both patient groups.RESULTSPatients showed no major clinical side-effects under this low dose treatment. As expected [¹⁷⁷Lu]Lu-P17-088 with longer blood circulation (due to its albumin binding) exhibited higher effective doses than [¹⁷⁷Lu]Lu-P17-087 (0.151 ± 0.036 vs. 0.056 ± 0.019 mGy/MBq, P = 0.001). Similarly, red marrow received 0.119 ± 0.068 and 0.048 ± 0.020 mGy/MBq, while kidney doses were 0.119 ± 0.068 and 0.046 ± 0.022 mGy/MBq, respectively. [¹⁷⁷Lu]Lu-P17-087 demonstrated excellent tumor uptake and faster kinetics; while [¹⁷⁷Lu]Lu-P17-088 displayed a slower washout and higher average dose (7.75 ± 4.18 vs. 4.72 ± 2.29 mGy/MBq, P = 0.018). After administration of [¹⁷⁷Lu]Lu-P17-087 and [¹⁷⁷Lu]Lu-P17-088, 3/5 and 3/4 patients showed reducing PSA values, respectively.CONCLUSION[¹⁷⁷Lu]Lu-P17-088 and [¹⁷⁷Lu]Lu-P17-087 displayed different pharmacokinetics but excellent PSMA-targeting dose delivery in mCRPC patients. These two agents are promising RLT agents for personalized treatment of mCRPC. Further studies with increased dose and frequency of RLT are warranted to evaluate the potential therapeutic efficacy.TRIAL REGISTRATION¹⁷⁷Lu-P17-087/¹⁷⁷Lu-P17-088 in Patients with Metastatic Castration-resistant Prostate Cancer (NCT05603559, Registered at 25 October, 2022). URL OF REGISTRY: https://classic.CLINICALTRIALSgov/ct2/show/NCT05603559 .

01 Jun 2024·European Journal of Nuclear Medicine and Molecular Imaging

Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa)

Article

Author: Gu, Di ; Liu, Yongda ; Wang, Xinlu ; Zhao, Ruiyue ; Xia, Zeheng ; Ke, Miao ; He, Yulu ; Zhu, Lin ; Sun, Tao ; Alexoff, David ; Zeng, Guohua ; Zhong, Huizhen ; Kung, Hank F ; Lv, Jie

PURPOSEThis paper discusses the optimization of pharmacokinetic modelling and alternate simplified quantification method for [¹⁸F]AlF-P16-093, a novel tracer for in vivo imaging of prostate cancer.METHODSDynamic PET/CT scans were conducted on eight primary prostate cancer patients, followed by a whole-body scan at 60 min post-injection. Time-activity curves (TACs) were obtained by drawing volumes of interest for primary prostatic and metastatic lesions. Optimal kinetic modelling involved evaluating three compartmental models (1T2K, 2T3K, and 2T4K) accounting for fractional blood volume (V_b). The simplified quantification method was then determined based on the correlation between the static uptake measure and total distribution volume (V_t) obtained from the optimal pharmacokinetic analysis.RESULTSIn total, 17 intraprostatic lesions, 10 lymph nodes, and 36 osseous metastases were evaluated. Visually, the contrast of the tumor increased and showed the steepest incline within the first few minutes, whereas background activity decreased over time. Full pharmacokinetic analysis revealed that a reversible two-compartmental (2T4K) model is the preferred kinetic model for the given tracer. The kinetic parameters K₁, k₃, V_b, and V_t were all significantly higher in lesions when compared with normal tissue (P < 0.01). Several simplified protocols were tested for approximating comprehensive dynamic quantification in tumors, with image-based SURmean (the ratio of tumor SUVmean to blood SUVmean) within the 28-34 min window found to be sufficient for approximating the total distribution V_t values (R² = 0.949, P < 0.01). Both V_t and SURmean correlated significantly with the total serum prostate-specific antigen (tPSA) levels (P < 0.01).CONCLUSIONSThis study introduced an optimized pharmacokinetic modelling approach and a simplified acquisition method for [¹⁸F]AlF-P16-093, a novel PSMA-targeted radioligand, highlighting the feasibility of utilizing one static PET imaging (between 30 and 60 min) for the diagnosis of prostate cancer. Note that the image-derived input function in this study may not reflect the true corrected plasma input function, therefore the interpretation of the associated kinetic parameter estimates should be done with caution.

01 May 2024·European Journal of Nuclear Medicine and Molecular Imaging

First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients

Article

Author: Zhang, Jing ; Ploessl, Karl ; Wang, Xinlu ; Liu, Yuheng ; Zhao, Ruiyue ; Alexoff, David ; Xu, Lifu ; Kung, Hank F ; Liu, Yongda ; Cai, Chao ; Ke, Miao ; Zhu, Lin ; Li, Mingzhao ; Gu, Di ; Zeng, Guohua ; Liu, Shaoyu ; Lv, Jie

PURPOSEThis is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [¹⁸F]AlF-P16-093, and also initial investigation of its ability to detect PSMA-positive tumors using PET scans in a cohort of prostate cancer (PCa) patients.METHODSThe [¹⁸F]AlF-P16-093 was automatically synthesized with a GE TRACERlab. A total of 23 patients with histopathologically proven PCa were prospectively enrolled. Dosimetry and biodistribution study investigations were carried out on a subset of six (6) PCa patients, involving multiple time-point scanning. The mean absorbed doses were estimated with PMOD and OLINDA software.RESULTS[¹⁸F]AlF-P16-093 was successfully synthesized, and radiochemical purity was > 95%, and average labeling yield was 36.5 ± 8.3% (decay correction, n = 12). The highest tracer uptake was observed in the kidneys, spleen, and liver, contributing to an effective dose of 16.8 ± 1.3 μSv/MBq, which was ~ 30% lower than that of [⁶⁸Ga]Ga-P16-093. All subjects tolerated the PET examination well, and no reportable side-effects were observed. The PSMA-positive tumors displayed rapid uptake, and they were all detectable within 10 min, and no additional lesions were observed in the following multi-time points scanning. Each patient had at least one detectable tumor lesion, and a total of 356 tumor lesions were observed, including intraprostatic, lymph node metastases, bone metastases, and other soft tissue metastases.CONCLUSIONSWe report herein a streamlined method for high yield synthesis of [¹⁸F]AlF-P16-093. Preliminary study in PCa patients has demonstrated its safety and acceptable radiation dosimetry. The initial diagnostic study indicated that [¹⁸F]AlF-P16-093 PET/CT is efficacious and potentially useful for a widespread application in the diagnosis of PCa patients.

100 Deals associated with Five Eleven Pharma, Inc.

100 Translational Medicine associated with Five Eleven Pharma, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 1 Clinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Gallium-68 P16-093 ( PSMA )	Prostatic Cancer More	Phase 2 Clinical
68Ga-P15-041	Prostatic Cancer More	Phase 1 Clinical
[18F]P17-059 ( VMAT2 )	Parkinson Disease More	Phase 1
FAP-α Imaging Agent (Five Eleven Pharma) ( FAP )	Neoplasms More	Preclinical
[177Lu]Lu-P17-079 ( PSMA )	Prostatic Cancer More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis